MK
Therapeutic Areas
BeyondSpring Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Plinabulin + G-CSF | Prevention of Chemotherapy-Induced Neutropenia (CIN) | Phase 3 |
| Plinabulin | Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 |
| BPI-002 | Undisclosed Oncology Target | Preclinical |
Leadership Team at BeyondSpring
DL
Dr. Lan Huang
Co-Founder, Chief Executive Officer, and Chairwoman of the Board
DR
Dr. Ramon Mohanlal
Former Chief Medical Officer and EVP of Research & Development
DD
Dr. Douglas Blayney
Scientific Advisory Board Member, Professor at Stanford University